Evidence map›Paper›PMID 34560105›Full record

ArticleThe Journal of allergy and clinical immunology2022

Airway administration of OM-85, a bacterial lysate, blocks experimental asthma by targeting dendritic cells and the epithelium/IL-33/ILC2 axis.

Vadim Pivniouk, Joao A Gimenes-Junior, Peace Ezeh, Ashley Michael, Oksana Pivniouk, Seongmin Hahn, Sydney R VanLinden, Sean P Malone, Amir Abidov, Dayna Anderson and 5 more

Open access · greenAbstract read
In one paragraph

Article in The Journal of allergy and clinical immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 54 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
54citing papers in PubMed, 1 pooled it
15.9field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

54 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Early Origins of Asthma and Allergies: Clues From Studies in China.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2025
    Review
  19. Review
  20. Mucosal immunotherapy targeting APC in lung disease.Journal of inflammation (London, England) · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Vadim PivnioukDepartment of Cellular and Molecular Medicine, The University of Arizona, Tucson, Ariz; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz; BIO5 Institute, The University of Arizona, Tucson, Ariz. Electronic address: vadimp@arizona.edu.
Joao A Gimenes-JuniorAsthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
Peace EzehAsthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
Ashley MichaelAsthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
Oksana PivnioukAsthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
Seongmin HahnAsthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
Sydney R VanLindenAsthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
Sean P MaloneAsthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
Amir AbidovMedical Student Research Program, College of Medicine, The University of Arizona, Tucson, Ariz.
Dayna AndersonAsthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
Justyna GozdzAsthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz.
Avery DeVriesAsthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz; BIO5 Institute, The University of Arizona, Tucson, Ariz.
Fernando D MartinezAsthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz; BIO5 Institute, The University of Arizona, Tucson, Ariz.
Christian PasqualiOM Pharma SA, Geneva, Switzerland.
Donata VercelliDepartment of Cellular and Molecular Medicine, The University of Arizona, Tucson, Ariz; Asthma and Airway Disease Research Center, The University of Arizona, Tucson, Ariz; BIO5 Institute, The University of Arizona, Tucson, Ariz; Arizona Center for the Biology of Complex Diseases, The University of Arizona, Tucson, Ariz.
University of Arizona · US

Funding

Recruitment, Data Collection & Sample Management CoreP01AI148104 · NIAID · UNIVERSITY OF ARIZONA · PI Tara F Carr, Susan Veronica Lynch · 2020 to 2026
$19.0M
PHYSIOLOGYT32HL007249 · NHLBI · UNIVERSITY OF ARIZONA · PI Brett A Colson, JOHN P KONHILAS · 1985 to 2026
$12.5M
Training in Environmental Toxicology of Human DiseaseT32ES007091 · NIEHS · UNIVERSITY OF ARIZONA · PI Nathan J Cherrington · 1985 to 2026
$10.7M
Role of Gamma delta-17 T Cells in Asthma Protection by Amish Farm Exposure .R21AI144722 · NIAID · UNIVERSITY OF ARIZONA · PI VERCELLI, DONATA · 2019 to 2020
$443k
NHLBI NIH HHS T32 HL007249NIAID NIH HHS P01 AI148104NIAID NIH HHS R21 AI144722NIEHS NIH HHS T32 ES007091
6 · The paper itself

Abstract

backgroundMicrobial interventions against allergic asthma have robust epidemiologic underpinnings and the potential to recalibrate disease-inducing immune responses. Oral administration of OM-85, a standardized lysate of human airways bacteria, is widely used empirically to prevent respiratory infections and a clinical trial is testing its ability to prevent asthma in high-risk children. We previously showed that intranasal administration of microbial products from farm environments abrogates experimental allergic asthma.

objectivesWe sought to investigate whether direct administration of OM-85 to the airway compartment protects against experimental allergic asthma; and to identify protective cellular and molecular mechanisms activated through this natural route.

methodsDifferent strains of mice sensitized and challenged with ovalbumin or Alternaria received OM-85 intranasally, and cardinal cellular and molecular asthma phenotypes were measured. Airway transfer experiments assessed whether OM-85-treated dendritic cells protect allergen-sensitized, OM-85-naive mice against asthma.

resultsAirway OM-85 administration suppressed allergic asthma in all models acting on multiple innate and adaptive immune targets: the airway epithelium/IL-33/ILC2 axis, lung allergen-induced type 2 responses, and dendritic cells whose Myd88/Trif-dependent tolerogenic reprogramming was sufficient to transfer OM-85-induced asthma protection.

conclusionsWe provide the first demonstration that administering a standardized bacterial lysate to the airway compartment protects from experimental allergic asthma by engaging multiple immune pathways. Because protection required a cumulative dose 27- to 46-fold lower than the one reportedly active through the oral route, the efficacy of intranasal OM-85 administration may reflect its direct access to the airway mucosal networks controlling the initiation and development of allergic asthma.

Indexed as

AsthmaInterleukin-33AllergensAnimalsBacterial LysatesCell ExtractsDendritic CellsDisease Models, AnimalEpitheliumHumansImmunity, InnateLungLymphocytesMiceMice, Inbred BALB COvalbuminAllergensBacterial LysatesBroncho-VaxomCell ExtractsInterleukin-33Ovalbuminadaptive immunityairway compartmentallergic inflammationasthmaBacterial lysateinnate immunityintranasal routemicrobial interventionsOM-85

Identifiers

PMID34560105
PMCPMC8901455
OpenAlexW3200680598

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.